Drug Trial Radar · NCT07923981
A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without Inhibitors
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
95
Planned (sponsor's estimate)
Start
Oct 23, 2026
Primary completion
Jul 2, 2029
Study completion Jun 16, 2032
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter study evaluating the efficacy and safety of marstacimab prophylaxis in approximately 95 male and female adolescents and adults aged 12 to \<75 years with mild to moderate hemophilia A or B without inhibitors who have a severe bleeding phenotype. Eligible participants must have baseline factor VIII or factor IX activity levels \>1% to ≤15% and a history of clinically significant bleeding despite prior treatment with either on-demand factor replacement therapy or routine factor prophylaxis. The study will compare bleeding outcomes and other efficacy measures during a historical 12-month period of prescribed factor replacement therapy prior to study entry with outcomes observed during a 12-month treatment phase in which participants receive marstacimab 150 mg administered subcutaneously once weekly. Participants will be enrolled into 2 cohorts based on their treatment regimen before study entry: a prior on-demand treatment cohort and a prior routine prophylaxis treatment cohort. Female participants with severe hemophilia A or B without inhibitors may also be enrolled on a case-by-case basis. Data from these participants will contribute to safety assessments, and separate descriptive analyses of efficacy outcomes will be performed for all female participants. The study will also evaluate the long-term safety and efficacy of marstacimab during a long-term extension (LTE) treatment phase of up to 36 months. Participants who complete the 12-month treatment phase may continue into the LTE phase. Participants may be in the study for approximately 50 months, including a 12-month treatment phase and a long-term extension phase of up to 36 months.
Conditions
- Hemophilia A or B
Interventions
marstacimabDrug
* Participants with mild to moderate hemophilia will receive 150 mg subcutaneous (SC) injection once weekly. * Female participants with severe hemophilia will receive 300 mg SC loading dose followed by 150 mg SC once weekly. A dose of 300 mg administered SC once weekly may be prescribed for participants who meet the dose-escalation criteria.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Bleeding Rate (ABR) of Treated Bleeding EventsTime frame: Baseline (up to 12 months prior to informed consent) up to end of 12-month treatment phase
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Southern Specialty Clinic
Flowood, Mississippi · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.